ID: ALA493612

Max Phase: Preclinical

Molecular Formula: C19H24ClFN2O2

Molecular Weight: 366.86

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(F)CCc1ccc(COc2cnn(C(C)(C)C)c(=O)c2Cl)cc1

Standard InChI:  InChI=1S/C19H24ClFN2O2/c1-13(21)5-6-14-7-9-15(10-8-14)12-25-16-11-22-23(19(2,3)4)18(24)17(16)20/h7-11,13H,5-6,12H2,1-4H3

Standard InChI Key:  MBOUAMRPAMORPE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 366.86

Molecular Weight (Monoisotopic): 366.1510

AlogP: 4.52

#Rotatable Bonds: 6

Polar Surface Area: 44.12

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 4.25

CX LogD: 4.25

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.75

Np Likeness Score: -0.90

References

1. Purohit A, Radeke H, Azure M, Hanson K, Benetti R, Su F, Yalamanchili P, Yu M, Hayes M, Guaraldi M, Kagan M, Robinson S, Casebier D..  (2008)  Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers.,  51  (10): [PMID:18422306] [10.1021/jm701443n]

Source

Source(1):

• Scientific Literature